Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Otsuka’s Pharma Sales Surge as Tolvaptan Grows Six-Fold in North America
February 17, 2020
- Teijin Pharma Set to Boost Partnerships in R&D, Seeking Licensee for Diabetic Nephropathy Drug: President
February 17, 2020
- Eisai Pulls Belviq from US Market after FDA Flags Cancer Risks
February 17, 2020
- Chugai, US Foundation Medicine Team Up with NCC for Blood-Based Genomic Testing
February 17, 2020
- StemRIM to Set Up Collaborative Lab in Osaka University
February 14, 2020
- Mitsubishi Chemical to Rev Up Next-Gen Therapy Biz to Enliven Pharma Unit: Chief
February 14, 2020
- Polatuzumab Vedotin Hits Main Goal in Japan PII for DLBCL: Chugai
February 14, 2020
- Ono Revamps Japan Sales Structure to Gear Up for New Launches
February 13, 2020
- Bayer’s Eylea Effective at Both 12-Week and 16-Week Intervals: PIV Study
February 13, 2020
- Astex’s Novel Cancer Drug Accepted for FDA Review: Otsuka
February 13, 2020
- Xtandi Extends Overall Survival in Non-Metastatic CRPC
February 13, 2020
- Followup Data Backs Padcev-Keytruda Combo for 1st Line Bladder Cancer: Astellas/Seattle Genetics
February 13, 2020
- In Japan Too, Pfizer and Mylan Prepping for Pending Viatris Integration
February 12, 2020
- With 2 New Deals Inked, Meiji Hunkering Down for Full-Scale Entry into Hematology Market
February 12, 2020
- Sumitomo Dainippon to Revise FY2022 Targets after Roivant Deal: President
February 10, 2020
- Chugai Joins NCC Scheme to Offer Free Drugs after Genomic Profiling
February 10, 2020
- After Erleada, Janssen Joins Hands with Nippon Shinyaku for Zytiga Too
February 10, 2020
- FDA Accepts Nippon Shinyaku’s DMD Drug for Review, Target Date Set for Q3 2020
February 10, 2020
- Stemirac Posts 130 Million Yen Sales in May-December: Nipro
February 10, 2020
- I’rom Teams Up with Shanghai Public Health Clinical Center to Tackle Novel Coronavirus
February 10, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…